Zomedica Financial Results
Zomedica reported record third-quarter revenue of $9.9 million, a 22% increase year-over-year, driven by strong demand for its PulseVet and Assisi therapeutic devices. The company significantly reduced its net loss by 48% and improved its cash burn by 32% to $3.2 million, marking its lowest third-quarter cash consumption on record.
- Term
- Q3 2026
“Zomedica delivered record third quarter revenue, continued year-over-year growth across our business, and made further progress in managing and improving upon operating costs and cash consumption.”
Larry Heaton, Chief Executive Officer of Zomedica
“Our results reflect sustained demand for our PulseVet® and Assisi® therapeutic device products, increasing adoption of our diagnostic offerings, and contributions from our Development Services segment.”
Larry Heaton, Chief Executive Officer of Zomedica